We're excited to announce our partnership with BridgeBio to generate insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. Read more about our partnership! https://invit.ae/3Si3n5I
Great example of celebrating diversity at Invitae!
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization
We continue to be committed to advancing our sustainable business practices and ESG efforts as part of our core mission to bring comprehensive genetic information into mainstream medicine. Please take a moment to read our Annual Environmental, Social and Governance (ESG) Report, which highlights our unique culture here at Invitae.
https://ir.invitae.com/news-and-events/press-releases/press-release-details/2023/Invitae-and-Deerfield-Management-Partner-to-Create-Novel-Therapeutics-for-Rare-Diseases/default.aspx
https://ir.invitae.com/news-and-events/press-releases/press-release-details/2023/Invitae-and-Deerfield-Management-Partner-to-Create-Novel-Therapeutics-for-Rare-Diseases/default.aspx
https://ir.invitae.com/news-and-events/press-releases/press-release-details/2023/Invitae-and-Deerfield-Management-Partner-to-Create-Novel-Therapeutics-for-Rare-Diseases/default.aspx
https://ir.invitae.com/news-and-events/press-releases/press-release-details/2023/Invitae-and-Deerfield-Management-Partner-to-Create-Novel-Therapeutics-for-Rare-Diseases/default.aspx
https://ir.invitae.com/news-and-events/press-releases/press-release-details/2023/Invitae-and-Deerfield-Management-Partner-to-Create-Novel-Therapeutics-for-Rare-Diseases/default.aspx
https://ir.invitae.com/news-and-events/press-releases/press-release-details/2023/Invitae-and-Deerfield-Management-Partner-to-Create-Novel-Therapeutics-for-Rare-Diseases/default.aspx
